antibody

Vascular Endothelial Growth Factor C (VEGF-C, VEGF-A, Vascular permeability factor, VPF)

V2121-30B

100 ul

polyclonal

domestic rabbit

nonconjugated

Vascular Endothelial Growth Factor C (VEGF-C, VEGF-A, Vascular permeability factor, VPF)

rabbit

Pab

Antibodies

100 ul

IgG

Vascular endothelial growth factor (VEGF) is a highly specific mitogen for vascular endothelial cells. VEGF and its close relatives VEGF-B, -C and -D form a subfamily within PDGF family of growth factors, which belongs to the cysteine knot class of cytokines. Five VEGF isoforms of 121, 145, 165, 189, and 206 amino acids (VEGF121– 206) are generated as a result of alternative splicing from a single VEGF gene (1). The various VEGF forms bind to three tyrosine-kinase receptors, VEGFR-1, VEGFR-2, and VEGFR- 3 which are expressed almost exclusively in endothelial cells. VEGFR-2 is the main angiogenic signal transducer for VEGF, while VEGFR-3 is specific for VEGF-C and -D and is necessary and sufficient for lymphangiogenic signaling. However, upon proteolytic processing VEGF-C and -D gain the ability to also bind and activate VEGFR-2 (2). Guided by the binding properties of the ligands, the VEGFRs are able to form both homodimers and heterodimers. Receptor dimerization is accompanied by activation of receptor kinase activity leading to receptor autophosphorylation. Phosphorylated receptors recruit interacting proteins and induce downstram signaling (3). Recently, tumor therapies based on neutralizing anti-VEGF antibodies and small molecule tyrosine kinase inhibitors targeting VEGFRs have been developed. These new strategies for tumor treatment show the clinical relevance of inhibiting VEGF signal transduction pathways that are exaggerated in pathological angiogenesis Applications: Suitable for use in ELISA and Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 1:1000 Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Hu

Synthetic peptide corresponding to residues surrounding Thr189 of human VEGF-C (KLH).

Recognizes recombinant human VEGF-C protein at ~21kD. Does not cross-react with other VEGF family members.

Purified by Protein A and peptide affinity chromatography.

Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol.

Not determined

Product Type: Pab Isotype: IgG Host: rabbit Source: human Concentration: Not determined Form: Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol. Purity: Purified by Protein A and peptide affinity chromatography. Immunogen: Synthetic peptide corresponding to residues surrounding Thr189 of human VEGF-C (KLH). Specificity: Recognizes recombinant human VEGF-C protein at ~21kD. Does not cross-react with other VEGF family members. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

E WB

-20°C

1) Olsson, A.K. et al. (2006) Nat. Rev. Mol. Cell. Biol. 7, 359–371.2) Gluzman-Poltorak, Z. et al. (2001) J. Biol. Chem. 276, 18688–18694. 3) Matsumoto, T. and Mugishima, H. (2006) J. Atheroscler. Thromb. 13, 130–135. 4) Gatto, B. and Cavalli, M. (2006) Anticancer Agents Med. Chem. 6, 287–301.

https://usbio-images.r.worldssl.net/prodimages/33/V2121-30B_1.jpg